Treatments | Concentrations (IJ-con/ml) | Observed mortality (%) | Expected mortality (%) | X2 | Type of interaction |
---|---|---|---|---|---|
M1 + S | 1000 + 5 × 107 | 20 | 30.6 | 3.7 | Additive |
M2 + S | 1000 + 5 × 107 | 20 | 30.6 | 3.7 | Additive |
M3 + S | 1000 + 5 × 107 | 20 | 42.2 | 11.7 | Antagonistic |
M4 + S | 1000 + 5 × 107 | 20 | 42.2 | 11.7 | Antagonistic |
B1 + S | 500 + 5 × 107 | 20 | 75.1 | 40.4 | Antagonistic |
B2 + S | 1000 + 5 × 107 | 33.3 | 48 | 4.5 | Antagonistic |
B3 + S | 1000 + 5 × 107 | 66.7 | 59.5 | 0.9 | Additive |
B4 + S | 1000 + 5 × 107 | 40 | 53.8 | 3.5 | Additive |
B5 + S | 1000 + 5 × 107 | 20 | 86.6 | 51.2 | Antagonistic |
B6 + S | 1000 + 5 × 107 | 53 | 59.3 | 0.7 | Additive |
B7 + S | 1000 + 5 × 107 | 33.3 | 48 | 4.5 | Antagonistic |
B8 + S | 1000 + 5 × 107 | 26.7 | 30.6 | 0.5 | Additive |
B9 + S | 1000 + 5 × 107 | 40 | 53.8 | 3.5 | Additive |
B10 + S | 1000 + 5 × 107 | 46.7 | 48 | 0 | Additive |
B11 + S | 1000 + 5 × 107 | 33.3 | 42.2 | 1.9 | Additive |
B12 + S | 1000 + 5 × 107 | 53.3 | 42.2 | 2.9 | Additive |
B13 + S | 1000 + 5 × 107 | 40 | 88.4 | 26.5 | Antagonistic |
B14 + S | 1000 + 5 × 107 | 93.3 | 56.7 | 23.7 | Synergistic |
B15 + S | 1000 + 5 × 107 | 40 | 53.8 | 3.5 | Additive |
B16 + S | 1000 + 5 × 107 | 40 | 48 | 1.3 | Additive |
B17 + S | 1000 + 5 × 107 | 33.3 | 48 | 4.5 | Antagonistic |
B18 + S | 1000 + 5 × 107 | 46.7 | 53.8 | 0.9 | Additive |
B19 + S | 1000 + 5 × 107 | 13.3 | 36.4 | 14.6 | Antagonistic |
B20 + S | 1000 + 5 × 107 | 20 | 42.2 | 11.7 | Antagonistic |
B21 + S | 1000 + 5 × 107 | 20 | 42.2 | 11.7 | Antagonistic |
B22 + S | 1000 + 5 × 107 | 33.3 | 48 | 4.5 | Antagonistic |
B23 + S | 1000 + 5 × 107 | 13.3 | 30.6 | 9.8 | Antagonistic |
B24 + S | 1000 + 5 × 107 | 0 | 30.6 | 30.6 | Antagonistic |
B25 + S | 1000 + 5 × 107 | 13.3 | 42.2 | 19.8 | Antagonistic |
B26 + S | 1000 + 5 × 107 | 0 | 30.6 | 30.6 | Antagonistic |
Control | 0 | 0 |